Comparison of Norethindrone-Containing OCPs to Desogestrel OCPs and Depo-Provera in Women

Abstract

This second summary report details the specific activities that have occurred during Year 2 of funding (September 23, 1997 through September 22, 1998). According to the SOW, 3 major objectives and related tasks were to be addressed during this period. Significant progress across each major objective was achieved. Recruitment was extended and will end on 31 October, 1998. To date, a total of 366 women have completed their initial medical visit with a projected enrollment of 375 women. Significant increases in enrollment at both sites was due to direct mail solicitation, hiring of a full-time research assistant, and HURRAD approval for a protocol change to modify the contraceptive wash-out period from 90 to 30 days for birth control pills and from 6 to 3 months for DMPA. Follow-up visits for the cohort have been excellent with 213, 148, and 40 subjects completing the 3, 6, and 12-month visits, respectively. Moreover, contraceptive discontinuation is projected to be significantly smaller than anticipated as only 53 (14.5%) women have discontinued their chosen contraceptive. Thus, our projected cohort of 375 women will allow use to meet all technical objectives.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 1998
Accession Number
ADA361594

Entities

People

  • Abbey B. Berenson

Organizations

  • University of Texas at Austin

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Active Duty
  • African Americans
  • Alkynes
  • Chemistry
  • Clinical Trials
  • Contraception
  • Diseases And Disorders
  • Health
  • Health Services
  • Materials
  • Medical Personnel
  • Musculoskeletal Physiology
  • Pain
  • Reproductive Control Agents
  • Side Effects
  • Spine
  • United States

Fields of Study

  • Medicine

Readers

  • Software Engineering
  • Technical Research and Report Writing.
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.